-
Description
Anexate Flumazenil 0.5mg Injection - 5ml Vial
Product Description:
Anexate Flumazenil 0.5mg Injection is a potent benzodiazepine antagonist indicated for the complete or partial reversal of the sedative effects of benzodiazepines in the management of benzodiazepine overdose. It is presented in a 5ml vial, containing 0.5mg of Flumazenil per ml, designed for intravenous administration.
Technician Specifications:
- Active Ingredient: Flumazenil 0.5mg per ml
- Volume: 5ml per vial
- Formulation: Clear, colorless, sterile solution for IV injection
- Storage: Store between 2°C to 8°C (36°F to 46°F)
- Shelf Life: Check packaging for expiry date
- Compatibility: Should not be mixed with other medications in the same syringe or infusion container
Common Applications:
- Reversal of conscious sedation and general anesthesia induced by benzodiazepines
- Management of suspected benzodiazepine overdose
- Diagnostic procedures to assess benzodiazepine tolerance or dependence
User Groups:
- Anesthesiologists and medical professionals in emergency departments
- Critical care and intensive care unit staff
- Medical personnel conducting diagnostic tests involving benzodiazepines
Supplier Overview:
Roche is a leading global healthcare company that specializes in diagnostics and pharmaceuticals. With a history spanning more than a century, Roche has established itself as an authority in the development and manufacturing of innovative medical solutions. Their commitment to research and development ensures that products like Anexate Flumazenil Injection are of the highest quality and efficacy. Roche's dedication to improving patient care and outcomes makes them a trusted supplier in the pharmaceutical industry, particularly in the realm of antidotes and critical care medications.
